Drugs / TG6002
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04194034 | Jan 2020 → Feb 2023 | colorectal neoplasm | Transgene | Terminated | No outcome recorded |
| Phase 1/2 | NCT03724071 | Oct 2018 → Feb 2023 | colorectal neoplasm | Transgene | Terminated | No outcome recorded |
| Phase 1/2 | NCT03294486 | Oct 2017 → May 2019 | brain cancer, glioblastoma | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TG6002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03724071 ↗ |
| Known as | VV TK-RR-FCU1 | “Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.” NCT03724071 ↗ |
| Route | Intravenous | “TG6002, administered as 3 weekly IV infusions” NCT03294486 ↗ |